Comparative Pharmacology
Head-to-head clinical analysis: LUXIQ versus POKONZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUXIQ versus POKONZA.
LUXIQ vs POKONZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
Topical: Apply a thin film to affected areas of the scalp twice daily (morning and evening) for 2 weeks; do not exceed 50 g per week.
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
None Documented
None Documented
Terminal half-life: 3-5 hours; in renal impairment may extend to 8 hours.
Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days
Renal: 30% unchanged; biliary/fecal: 70% as metabolites.
Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid